Navigation Links
Insmed Retains RBC Capital Markets as Strategic Financial Advisor
Date:7/14/2008

a meeting with the FDA to discuss potentially initiating a Phase III clinical trial program for INS-19. The Company also intends to initiate human bioequivalence clinical studies for INS-20 in the fourth quarter of 2008, with data expected in the first quarter of 2009. Insmed has several other FOB products which are currently at an earlier stage of cell line development and product characterisation.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that strategic alternatives may never be consummated, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, our common stock coul
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lkcspr/2015_strategies ... "2015 Strategies in European Immunoprotein Diagnostic ... This new 273-page report provides ... including emerging tests, technologies, instrumentation, sales forecasts, ... suppliers. Companies Mentioned: - ...
(Date:6/1/2015)... June 1, 2015  OncoSec Medical Inc. ("OncoSec") ... intratumoral cancer immunotherapies, today announced a collaboration with ... Veterinary Medicine to test ImmunoPulse™ IL-12 as an ... primary goals of the canine study are to ... of ImmunoPulse™ IL-12 and validate key clinical biomarkers. ...
(Date:6/1/2015)... Hutchison China MediTech Limited ... (publ) ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, ... clinical trial of HMP,s c-Met inhibitor savolitinib (AZD6094) ... cell lung cancer ("NSCLC"). AZD9291 is ... receptor (EGFR). Preliminary data on the activity of ...
(Date:5/31/2015)... 31, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... oncology and drug-delivery therapies, today announced interim findings ... its investigational new drug PEGPH20 for the potential ... The encouraging interim data was presented today ... meeting in an oral presentation by Principal Investigator ...
Breaking Biology Technology:OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 2OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 4Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 2Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 4Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 5
... AMGN ) Senior Vice President of Research and ... U.S. Food and Drug Administration (FDA) panel charged with implementing ... patient safety and follow a science-based approach. "Put ... "Amgen believes biosimilars have a meaningful role to play in ...
... November 1, 2010 ... ... --> ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r in ...
... Influenza Vaccine ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
Cached Biology Technology:Amgen to Provide Testimony at FDA Hearing on Biosimilars 2Amgen to Provide Testimony at FDA Hearing on Biosimilars 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 4Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 2Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 3Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 4Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 5Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 6Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 7Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 8Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 9Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 2Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 3Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 4Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 5Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 6Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 7Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 8
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... virus discovered last year in a rare form of skin ... most common form of skin cancer among Americans, according to ... James Cancer Hospital and Solove Research Institute. The researchers examined ... a highly curable form of skin cancer that is expected ...
... A team of 80 researchers from more than ... Environmental and Cultural Change in Maryland,s Coastal Bays, a ... making up Maryland,s Atlantic coastline. Published by IAN ... setting, context and ecology of these waterways, their islands ...
... adults who have less strength, poor physical function and low muscle ... with more strength and better function. That,s the finding of a ... . The study also found that muscle density, a measure ... the muscle, is a more accurate gauge of a person,s risk ...
Cached Biology News:Study links virus to some cases of common skin cancer 2Reducing risk of hospitalization in the elderly 2
Nestin, Human...
Ezrin/Radixin/Moesin Antibody...
... Taura Syndrome Virus Coat Protein ... tested applications). ... MNDIPITNQN VVLSKNVTDN LFEVQDQALI ESLSRDVLLH NDSWTSSDDE ... terminal amino acids 25/100 of ...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
Biology Products: